Biological Background of GPC2

Glypican-2 (GPC2) is a member of the glypican family of heparan sulfate proteoglycans (HSPGs), which are cell-surface molecules anchored to the plasma membrane via a glycosylphosphatidylinositol (GPI) linkage. The glypican family comprises six members in mammals (GPC1–GPC6), each sharing a conserved core protein structure with a characteristic cysteine-rich domain and attachment sites for heparan sulfate (HS) chains.

GPC2 is expressed predominantly in the nervous system, particularly during embryonic and early postnatal development, where it plays important roles in modulating cell proliferation, differentiation, and axonal growth. The heparan sulfate chains of GPC2 interact with a variety of growth factors and morphogens — including FGF, Wnt ligands, and hedgehog proteins — acting as co-receptors or modulators of ligand-receptor interactions at the cell surface.

In recent years, GPC2 has attracted significant attention in oncology as a highly expressed surface antigen in neuroblastoma, a common pediatric solid tumor. This restricted expression pattern on tumor cells with low expression in normal adult tissues makes GPC2 an attractive target for immunotherapy strategies such as CAR-T cell therapy and antibody-drug conjugates (ADCs).

Protein Properties and Formulation

Recombinant Human GPC2 Protein (rp368045) is produced using recombinant expression systems to yield a high-purity protein suitable for use in research applications. The recombinant form typically encompasses the extracellular domain of GPC2, allowing it to be used in solution-phase and solid-phase assays without the constraints of the native GPI membrane anchor.

Key physicochemical properties of GPC2 include its large extracellular domain, which contains the characteristic cysteine-rich globular core, and the covalently attached heparan sulfate glycosaminoglycan chains that contribute significantly to the molecular weight of the native proteoglycan. Researchers should note that the apparent molecular weight observed by SDS-PAGE may differ from the predicted molecular weight of the protein backbone due to glycosylation and glycosaminoglycan modification.

For optimal performance, the protein should be reconstituted according to the manufacturer's instructions using an appropriate buffer (typically PBS or a carrier protein-supplemented buffer), aliquoted to minimize freeze-thaw cycles, and stored at -80°C for long-term stability. Working stocks may be kept at 4°C for short periods but extended storage at this temperature is not recommended.

Recommended Applications and Protocols

ELISA: Recombinant Human GPC2 Protein is suitable for use as a capture or detection antigen in enzyme-linked immunosorbent assays. Coat the ELISA plate with GPC2 protein at a concentration typically in the range of 1–4 µg/mL in carbonate-bicarbonate coating buffer (pH 9.6) overnight at 4°C. Block with 1–5% BSA or non-fat dried milk in PBS-T, then incubate with the primary antibody of interest.

Western Blot: The recombinant protein may be used as a positive control in Western blot experiments. Load an appropriate amount (typically 50–200 ng per lane) alongside samples. After SDS-PAGE and transfer, probe the membrane with an anti-GPC2 antibody. Note that the apparent band size may be higher than predicted due to glycosylation.

Cell-Based and Binding Assays: Recombinant GPC2 can be used in binding studies to evaluate the interaction of GPC2 with growth factors, antibodies, or other binding partners. Surface plasmon resonance (SPR) and biolayer interferometry (BLI) are suitable biophysical methods for measuring binding kinetics and affinity. In cell-based experiments, recombinant GPC2 can be used to study the effects of soluble GPC2 on cell signaling or proliferation.

Immunotherapy Research: Given GPC2's role as a neuroblastoma surface antigen, the recombinant protein is useful for screening and validating antibodies intended for therapeutic development, including those for CAR-T cell or ADC applications.

Handling, Storage, and Quality Considerations

Reconstitution: If the protein is supplied in lyophilized form, allow the vial to equilibrate to room temperature before opening. Reconstitute by adding the volume of sterile ultrapure water or the recommended buffer as stated on the product datasheet. Gently pipette to mix; do not vortex, as this may cause protein aggregation or denaturation.

Storage: For long-term storage, aliquot the reconstituted protein into single-use volumes and store at -80°C. Avoid repeated freeze-thaw cycles, which can reduce protein activity and increase aggregation. Short-term storage (up to 1 week) at 4°C is acceptable if a carrier protein such as 0.1% BSA is included.

Quality Control: Each lot of Recombinant Human GPC2 Protein should be characterized by SDS-PAGE and/or Western blot to confirm identity and purity. Endotoxin levels should be below acceptable thresholds for cell-based assays (typically <1.0 EU/µg). Researchers are advised to request the Certificate of Analysis (CoA) for each lot to review all QC data.

Handling Precautions: Handle the protein on ice whenever possible. Use low-binding plasticware to minimize adsorption losses, particularly at low protein concentrations. Standard laboratory safety practices apply; consult the Safety Data Sheet (SDS) before use.

GPC2 in Neuroblastoma and Translational Research

Neuroblastoma is one of the most common extracranial solid tumors in children, and high-risk cases carry a poor prognosis despite intensive multimodal therapy. GPC2 has emerged as a promising cell-surface oncotarget due to its high and relatively uniform expression on neuroblastoma cells, while expression in normal adult tissues remains low. This differential expression profile is critical for the therapeutic window of GPC2-directed therapies.

Preclinical studies have demonstrated that GPC2-directed antibody-drug conjugates and CAR-T cells can selectively kill GPC2-expressing neuroblastoma cells in vitro and in mouse xenograft models. Recombinant Human GPC2 Protein is a valuable reagent in this research context for antibody screening, affinity maturation, and functional validation of GPC2-targeting therapeutics.

Beyond neuroblastoma, GPC2 expression has been reported in other tumor types, and its role in developmental signaling pathways continues to be investigated. Researchers studying Wnt, FGF, or hedgehog signaling in cancer or development may find Recombinant Human GPC2 Protein useful as a tool to dissect GPC2's co-receptor functions in these pathways.